Format

Send to

Choose Destination
Pediatr Blood Cancer. 2009 Sep;53(3):505-8. doi: 10.1002/pbc.21988.

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

Author information

1
Children's Hospital of Los Angeles, Los Angeles, California 90027, USA. nkeshelava@chla.usc.edu

Abstract

Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

PMID:
19418547
PMCID:
PMC2752378
DOI:
10.1002/pbc.21988
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center